1.866.339.0871         info@promab.com  info@promab.com

CAR-T/NK PLATFORM

Major Services

Immunotherapy is emerging as a highly promising approach for the treatment of cancer. T cells (T lymphocytes), the armed forces of our immune system, constantly look for foreign antigens and discriminate abnormal (cancer or infected cells) from normal cells. Genetically modifying T cells with Chimeric Antigen Receptors (CAR)s is the most common approach to generate tumor-specific T cells. CAR-T cells targeting tumor-associated antigens can be infused into patients and attack the tumor.

ProMab Biotechnologies has developed many CAR-T products based on 15 years' experience on hybridomas, monoclonal antibodies (rabbit, mouse, and human), recombinant proteins, and cancer stem cells. ProMab's new custom CAR-T service is designed to take advantage of the astonishing clinical breakthroughs of CAR-T cells against various hematological malignancies.

ProMab Biotechnologies can construct CARs based on your antibody sequence or can generate a mouse or fully human single-chain variable fragment (scFv) for the CARs. PrMab has generated more than 25 types of CAR-T cells (and CAR-NK cells) targeting different tumor cells and cell lines expressing tumor-specific antigens. These CAR-T cells can be used with immunological modulators, tumor microenviroment invaders, or checkpoint inhibitors. In addition, ProMab has developed sensitive real-time cytotoxicity assays (RTCA) for CAR-T cell validation in vitro and ex vivo. ProMab has also developed in vivo NSG/ NOG xenograft models to test CAR-T cell anti-cancer activity in hematological and solid cancers.

CONSTRUCT DESIGN
CONSTRUCT DESIGN

Most Popular Service Plans And Prices

PLAN A
Development Stage Description Cost
Phase I (optional) Immunization of Balb/C mice with recombinant protein or carrier-conjugated peptide. Generation of hybridoma cell lines following antibody validation against the correctly-presented antigen. $3,900
Phase II (optional) Sequencing of the antibody's heavy and light chains. $1,600
Phase III Synthesis and cloning of an scFv with selected CAR domains into a lentivirus vector. Generation of 1x108 lentivirus viral particles. $6,000
Phase IV T cell activation, lentiviral transduction, and CAR-T expansion. $5,000
Phase V Measurements of CAR expression, INF-γ & IL-2 induction and cytotoxicity. $6,000
PLAN B
Development Stage Description Cost
Phase III-I Synthesis and cloning of an scFv with selected CAR domains into a lentivirus vector. Generation of 1x108 lentivirus viral particles. $6,000
Phase IV T cell activation, lentiviral transduction, and CAR-T expansion. $5,000
Phase VI NSG/NOG xenograft model starting at $15,000